First Zantac Cancer Risk Trial in California Postponed by Months

The first scheduled trial over claims that GSK's heartburn drug Zantac caused cancer, which had been set to begin Monday, has been postponed, likely by several months.
Reuters Health Information

source https://www.medscape.com/viewarticle/988802?src=rss

Comments

Popular posts from this blog

New AAFP practice guideline sets blood pressure targets for adults with hypertension

RA and RA-ILD Linked to Higher Lung Cancer Risk

A Large Multicenter Prospective Study of Community-Onset Healthcare Associated Bacteremic Urinary Tract Infections in the Era of Multidrug Resistance: Even Worse than Hospital Acquired Infections?